Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTPGQ3)

Drug Name
MS1943 Drug Info
Synonyms
2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Investigative [1]
Cross-matching ID
PubChem CID
139211327
TTD Drug ID
DMTPGQ3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Enhancer of zeste homolog 2 (EZH2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tazemetostat DMWP1BH Follicular lymphoma 2A80 Approved [2]
DS-3201b DMI69E5 T-cell leukaemia 2A90 Phase 2 [3]
CPI-1205 DM3XWJ8 Prostate cancer 2C82.0 Phase 1/2 [4]
SHR2554 DMMUCH0 Prostate cancer 2C82.0 Phase 1/2 [1]
CPI-0209 DMJEXLI Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
DS-3201 DMRLPFG Acute lymphoblastic leukaemia 2A85 Phase 1 [4]
HH2853 DMQIE58 Non-hodgkin lymphoma 2B33.5 Phase 1 [6]
GSK2816126 DMJDVW4 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
PF-06821497 DML3WT6 Diffuse large B-cell lymphoma 2A81 Phase 1 [8]
PMID28394193-Compound-56 DMQRFZK N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Enhancer of zeste homolog 2 (EZH2) TT9MZCQ EZH2_HUMAN Degrader [1]

References

1 Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
3 Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
6 Clinical pipeline report, company report or official report of HaiHe Biopharma.
7 National Cancer Institute Drug Dictionary (drug id 756211).
8 Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665.
9 EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.